Read by QxMD icon Read


Giovanni Faria Silva, Vanessa Gutierrez de Andrade, Alecsandro Moreira
BACKGROUND: The infection for the hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality through its evolution to liver cirrhosis, end-stage liver complications and hepatocellular carcinoma. Currently, the new drugs for the HCV infection, based on direct antiviral agents, have changed the outcomes in this setting. OBJECTIVE: To assess death incidence, during the wait for the treatment with the new drugs, and to analyze which independent variable (age, sex, ascite, HDA, albumin, α-fetoprotein, platelets and Meld score) had relation with death...
October 2018: Arquivos de Gastroenterologia
Martina Vitrone, Antonio Parrella, Rosina Albisinni, Emanuele Durante-Mangoni, Rosa Zampino
Current regimens of direct-acting antiviral agents (DAA) are effective and safe for chronic hepatitis C (CHC). However, DAA often interfere with concomitant medications. We treated seven CHC patients with DAA who were on chronic anticoagulant treatment with warfarin, and describe the dynamics of prothrombin time, providing novel data, useful for the clinician.
February 20, 2019: Journal of Chemotherapy
Elsie-Jane Anastasius, Halimuddin Sawali
Introduction: Double aortic arch (DAA) is a congenital anomaly of the aortic arch. It is the most common type of complete vascular ring. When it occurs, the connected segment of the aortic arch and its branches encircle the trachea and esophagus, leading to symptoms related to these two structures. Case Report: We present a case of a newborn baby who developed biphasic stridor immediately after a normal vaginal delivery. Endoscopic assessment of the trachea revealed a pulsatile narrowing at the level of the thoracic trachea, suggestive of an external compression...
January 2019: Iranian Journal of Otorhinolaryngology
Goki Suda, Chitomi Hasebe, Masami Abe, Masayuki Kurosaki, Jun Itakura, Namiki Izumi, Yoshihito Uchida, Satoshi Mochida, Hiroaki Haga, Yoshiyuki Ueno, Kazumichi Abe, Atsushi Takahashi, Hiromasa Ohira, Yoko Tsukuda, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Jun Inoue, Katsumi Terasita, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
BACKGROUND: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and safety; however, the number of GT2 HCV-infected patients, especially Asian patients, was limited and most of them were treated with a 12-week regimen. In this prospective multicenter study, we aimed to investigate the efficacy and safety of G/P in Japanese hemodialysis patients with GT2 HCV infection...
February 18, 2019: Journal of Gastroenterology
Minou van Seyen, Marga J A de Graaff Teulen, Nielka P van Erp, David M Burger
Direct-acting antivirals (DAA) have markedly improved the treatment of hepatitis C, with a series of DAA combinations available for treatment. A sensitive method by ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the simultaneous quantification of seven commonly used DAAs, daclatasvir (DAC), elbasvir (ELB), grazoprevir (GZR), ledipasvir (LDV), simeprevir (SIM), sofosbuvir (SOF), velpatasvir (VEL) and the primary analyte of interest of SOF (GS-331007) in EDTA plasma...
January 28, 2019: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Juliet A Emamaullee, Mariusz Bral, Glenda Meeberg, Aldo J Montano-Loza, Vincent G Bain, Kelly Warren Burak, David Bigam, A M James Shapiro, Norman Kneteman
Background: The introduction of direct-acting antivirals (DAA) for HCV has led to high rates of HCV eradication. Treatment of patients awaiting liver transplantation (LT) has been controversial. Recent data suggests that DAA treatment may accelerate recurrent HCC. The impact of DAA on delisting for HCC progression or recurrent HCC post-LT has not been well characterized. Methods: A retrospective review of both waitlist patients and LT recipients at a single institution was performed...
2019: Canadian Journal of Gastroenterology & Hepatology
Ewelina Marciniewicz, Przemysław Podgórski, Tomasz Pawłowski, Krzysztof Małyszczak, Katarzyna Fleischer-Stępniewska, Brygida Knysz, Marta Waliszewska-Prosół, Agnieszka Żelwetro, Weronika Rymer, Małgorzata Inglot, Maria Ejma, Marek Sąsiadek, Joanna Bladowska
The study was performed to evaluate cerebral volume changes in HCV-infected subjects before and after interferon-free therapy with direct-acting antiviral agents (DAA). We aimed also to estimate the impact of successful DAA therapy on the neuropsychological state of patients. Eleven HCV genotype 1 (GT1) patients treated with ombitasvir/paritaprevir (boosted with ritonavir) and dasabuvir, with or without ribavirin underwent brain magnetic resonance (MR) before and 24 weeks after completion of therapy. All patients achieved sustained viral response...
February 7, 2019: Journal of the Neurological Sciences
Antonio Klasan, Thomas Neri, Ludwig Oberkircher, Dominik Malcherczyk, Thomas Jan Heyse, Christopher Bliemel
BACKGROUND: The direct anterior approach (DAA) has gained popularity in total hip arthroplasty (THA) over the past decade. A large number of studies have compared the DAA to other approaches with inclusion of a learning curve phase. The aim of this study was to compare the complication rate and bleeding between the DAA and the anterolateral approach after the learning curve phase. METHODS: For this retrospective, single-institutional study, propensity score matching was performed, from an initial cohort of 1408 patients receiving an elective THA...
February 14, 2019: BMC Musculoskeletal Disorders
Luisa Salazar-Vizcaya, Roger D Kouyos, Karin J Metzner, Kamila Caraballo Cortes, Jürg Böni, Cyril Shah, Jan Fehr, Dominique L Braun, Enos Bernasconi, Herbert A Mbunkah, Matthias Hoffmann, Niklaus Labhardt, Matthias Cavassini, Mathieu Rougemont, Huldrych F Günthard, Olivia Keiser, Andri Rauch
Background: Scale-up of direct-acting antiviral(DAA) therapy is expected to abate HCV incidence among HIV-positive men-who-have-sex-with-men(MSM). Treatment programs in neighbouring countries may influence each other's outcomes through international transmission. We aimed at classifying HCV infections in HIV-positive MSM as either domestically or internationally acquired, and at estimating how this classification changed over time. Methods: HCV subtype 1a (the most frequent subtype among MSM) genomes from 99 persons enrolled in the Swiss-HIV-Cohort-Study(SHCS) and diagnosed with replicating HCV infections between 1999 and 2016, were sequenced...
February 13, 2019: Journal of Infectious Diseases
Amr Shaaban Hanafy, Mohamed A Bassiony, Mohammad Abd Alkhalik Basha
BACKGROUND: Medical treatment of decompensated cirrhosis due to hepatitis C virus (HCV) remains a clinical challenge even in the era of direct-acting antiviral drugs (DAAs). We evaluated the efficacy and safety of DAAs in the management of HCV genotype 4-related decompensated cirrhosis. METHODS: The study included a treatment group (n = 160) composed of HCV patients with decompensated cirrhosis who received DAAs for 3 months and a matched control group (n = 80) who preferred not to receive DAAs, follow-up was for 24-31 months...
February 13, 2019: Hepatology International
Mariantonietta Pisaturo, Mario Starace, Carmine Minichini, Stefania De Pascalis, Margherita Macera, Laura Occhiello, Vincenzo Messina, Vincenzo Sangiovanni, Ernesto Claar, Davide Precone, Gianfranca Stornaiuolo, Maria Stanzione, Ivan Gentile, Giuseppina Brancaccio, Salvatore Martini, Addolorata Masiello, Angelo Salomone Megna, Carmine Coppola, Alessandro Federico, Evangelista Sagnelli, Marcello Persico, Alfonso Galeota Lanza, Aldo Marrone, Giovanni Battista Gaeta, Nicola Coppola
BACKGROUND: This real-world clinical-setting study characterized the virological patterns in genotype-1 patients failing IFN-free regimens and evaluated the efficacy of re-treatment. METHODS: Seventy-three consecutive patients failing IFN-free regimens were enrolled (17 genotype 1a and 56 1b). At failure Sanger sequencing of NS3, NS5A and NS5B regions was performed by home-made protocols. RESULTS: In patients having failed an NS3 inhibitor, the prevalence of NS3-RASs was higher in the 10 with genotype 1a than in the 24 with genotype 1b (80% vs...
February 13, 2019: Antiviral Therapy
Stefan Mauss, Lukas Buendgens, Stefan Christensen, Patrick Ingiliz, Florian Berger, Dietrich Hüppe, Karl Georg Simon, Thomas Lutz, Knud Schewe, Christoph Boesecke, Frank Tacke
BACKGROUND AND AIMS:  Disease activity, but also demographics, lifestyle, and comorbidities, may influence alanine aminotransferase (ALT) levels in hepatitis C virus (HCV)-infected patients. Direct-acting antiviral agents (DAA) achieve virological cure in > 90 % of patients, regardless of HCV genotype and fibrosis stage. This allows assessing determinants for ALT levels before and after elimination of HCV. METHODS:  Our prospective cohort included HCV- and HIV/HCV-infected patients treated with DAA at 9 German centers (GECCO cohort)...
February 2019: Zeitschrift Für Gastroenterologie
Rui-Feng Yang, Yan Liu, Cai-Yan Zhao, Ya-Xing Ding, Yu Chen, Ya-Dong Wang, Zhong-Ping Duan
Recent advance in the direct-acting antivirals (DAAs) offers the potentials to eradicate hepatitis C virus (HCV) worldwide and makes universal screening more urgent. A point-of-care (POC) oral anti-HCV assay, the Fortune assay, was developed and its performance was evaluated. Individuals with or without HCV infection were recruited in three Centers. Paired oral and serum samples were tested using the Fortune and InTec anti-HCV assays. The Kehua serum anti-HCV assay served as a supplemental test to verify the discordant results...
2019: PloS One
Kosuke Iwane, Takahisa Kayahara, Hiroyuki Takabatake, Yoichi Morimoto, Akiko Iseki, Motowo Mizuno, Kenji Notohara
A Japanese male in his 70s with chronic hepatitis C was diagnosed with diffuse large B-cell lymphoma and achieved and maintained complete remission following treatment with eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisolone). Seven years later, he received the direct-acting antivirals (DAAs) sofosbuvir/ledipasvir for hepatitis C virus (HCV) genotype 1b. Although the patient achieved sustained virological response immediately after the initial treatment period, laboratory data showed elevation of LD and soluble IL-2R...
2019: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
Emma Day, Tina Broder, Julie Bruneau, Sally Cruse, Melisa Dickie, Suzanne Fish, Celine Grillon, Niklas Luhmann, Kate Mason, Elizabeth McLean, Stacey Trooskin, Carla Treloar, Jason Grebely
It is estimated that 6.1 million people with recent injecting drug use (PWID) are living with hepatitis C virus (HCV). Although HCV-related morbidity and mortality among PWID continues to increase, the advent of direct acting antiviral (DAA) HCV regimens with cure rates >95% provides an opportunity to reverse the rising burden of disease. Additionally, given evidence that opioid substitution therapy and high-coverage needle and syringe programs can reduce HCV incidence by up to 80%, there is an opportunity to reduce HCV transmission with increased coverage of harm reduction services...
February 8, 2019: International Journal on Drug Policy
Chung-Feng Huang, Ming-Lung Yu
During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have always been excluded. Apart from the clinical trials, more HCC patients are currently being treated in daily practice, given that these treatments are highly effective and involve well-tolerated regimens. Large scale, real-world studies have demonstrated potentially suboptimal antiviral treatment efficacy in HCC patients who received DAAs...
February 11, 2019: Clinical and Molecular Hepatology
Jun-Il Yoo, Yong-Han Cha, Kap-Jung Kim, Ha-Yong Kim, Won-Sik Choy, Sun-Chul Hwang
BACKGROUND: Comparative studies of total hip arthroplasty using the direct anterior approach (DAA) compared with the anterolateral approach (ALA) by gait analysis compared the results of the two groups, the damage to the abductor muscle, with objective and detailed kinematic as well as kinetic data of actual gait. The purpose of this systematic review was to analyze the differences in gait such as time-dependent parameters, kinetics, and kinematics after THA using the DAA compared with ALA...
February 8, 2019: BMC Musculoskeletal Disorders
S Amele, L Peters, M Sluzhynska, A Yakovlev, A Scherrer, P Domingo, J Gerstoft, J P Viard, M Gisinger, R Flisiak, S Bhaghani, M Ristola, C Leen, E Jablonowska, G Wandeler, H Stellbrink, K Falconer, A D'Arminio Monforte, A Horban, J K Rockstroh, J D Lundgren, A Mocroft
OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure...
February 8, 2019: HIV Medicine
Pin-Nan Cheng, Ju-Yi Chen, Yen-Cheng Chiu, Hung-Chih Chiu, Liang-Miin Tsai
Chronic hepatitis C (CHC) is strongly associated with risks of cardiovascular diseases. The impact of direct acting antiviral (DAA) therapy on central blood pressure remains unclear. This investigation evaluates changes in central blood pressure following DAA therapy. One hundred and two DAA-treated patients were prospectively enrolled. Lipid profiles and pulse wave analysis of brachial artery by cuff sphygmomanometry including augmentation index (AIx), a parameter of central artery stiffness, were evaluated...
February 5, 2019: Scientific Reports
Juanli Liu, Peng Liu
Conducting polymers and their hybrids have attracted significant attention in electrochemical capacitors due to their unique electrochemical properties. However, the poorer cycle life and lower rate capability have greatly restricted their practical applications. Herein, well-defined poly(1,5-diaminoanthraquinone)/reduced graphene oxide hybrids (PDAA/rGO) with excellent electrochemical performance were successfully prepared via in-situ chemical oxidation polymerization of 1,5-diaminoanthraquinone (DAA) using HClO4 as initiator and (NH4 )2 S2 O8 as oxidant in organic solvent mixture at room 25 °C...
January 30, 2019: Journal of Colloid and Interface Science
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"